Smaller biotech and early-stage companies will drive next-generation approaches to developing immunotherapy drugs in the coming years, according to a WuXi AppTec report. The next decade will see bigger innovations as the industry increases its understanding of the immune system, the report said, with smaller companies more aggressively bringing new therapies to market.
Report: Smaller companies to drive immunotherapy innovation
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.